CDC says heart inflammation cases in 16-24 year olds are higher than expected after second injection
A young man from West Virginia receives the vaccine while overlooking the West Virginia Capitol at Riggleman Hall.
Stephen Zenner | LightRocket | Getty Images
The number of cases of heart inflammation among 16 to 24 year olds was higher than expected after receiving their second dose of Pfizer or Moderna Covid-19 vaccines, the Centers for Disease Control and Prevention said on Thursday, citing preliminary information. data from its vaccine safety monitoring system.
There have been 275 reported cases of myocarditis or pericarditis, which are inflammatory conditions involving the heart, in people aged 16 to 24 as of May 31, according to a CDC presentation that was prepared for an advisory group meeting. from the Food and Drug Administration Thursday.
The FDA’s Vaccines and Related Biologics Advisory Committee is holding a meeting to discuss the use of Covid-19 vaccines in children as young as 6 months old.
The expected number of cases was between 10 and 102, according to the CDC.
There have been a total of 475 reported cases of myocarditis or pericarditis in people 30 and under, according to the CDC. Most of the hospital patients, or 81% of them, have fully recovered from their system, the agency said. As of May 31, 15 people remained hospitalized, including three in intensive care.
The majority of cases appear to occur in men, and the median time to onset of symptoms is two to three days, according to the CDC.
The CDC’s vaccine safety group said last month it was studying conditions of heart inflammation in “relatively few” people who have received Covid vaccines.
The cases mostly involved adolescents and young adults and typically occurred within four days of the injection, the CDC said at the time. The condition has been seen more often in men and most cases appear to be mild, the agency said, although authorities are monitoring patients.
The CDC is coordinating its investigation with the FDA, which last month cleared the Pfizer-BioNTech vaccine for teens ages 12 to 15.
“We still don’t know if this is really vaccine-related,” Dr. Peter Marks, director of the FDA’s Center for Biologics Evaluation and Research, said in a virtual question-and-answer event on May 27. He added that “the handful” of reported cases have been “very mild, lasting a day or two” and have generally occurred after a second dose.
This is a developing story. Please check for updates.